Track Can-Fite BioPharma Ltd. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Can-Fite BioPharma Ltd. CANF · Stock Open Can-Fite BioPharma Ltd. in new tab

2.21 USD
Add to portfolio
EPS
-4.65
P/B
0.98
ROE
-211.37
Beta
-0.04
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateApril 1, 2027
EPS-4.65
Book Value2.27
Price to Book0.98
Debt/Equity1.01
Growth
Revenue Growth-0.43%
Estimates
Forward P/E-8.26
Forward EPS-0.27

DCF Valuation

Tweak assumptions to recompute fair value for Can-Fite BioPharma Ltd. (CANF)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Can-Fite BioPharma Ltd. Logo Can-Fite BioPharma Ltd. Analysis (CANF)

Israel Health Care Official Website Stock

Is Can-Fite BioPharma Ltd. a good investment? Can-Fite BioPharma Ltd. (CANF) is currently trading at 2.21 USD.

Earnings Schedule: Can-Fite BioPharma Ltd. is expected to release its next earnings report on April 1, 2027. The market consensus estimate for Forward EPS is -0.27.

Investor FAQ

Does Can-Fite BioPharma Ltd. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Can-Fite BioPharma Ltd.?

Can-Fite BioPharma Ltd. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be April 1, 2027. The company currently has a trailing EPS of -4.65.

Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, It offers cannabinoids for treatment of conditions associated with elevated expression of the A3 adenosine receptors. Further, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.

Exchange Ticker
ASE (United States) CANF
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
May 10, 2019 Needs review
Jan. 9, 2023 1:10
Jan. 5, 2026 1:20
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion